Core Insights - PetVivo Holdings, Inc. has formed a strategic alliance with Digital Landia Corp. to integrate innovative AI technology into its veterinary products, creating a global pet care ecosystem focused on animal health [1][5] Partnership Structure and Strategic Benefits - PetVivo will invest $150,000 in restricted common stock for a 2% equity stake in Digital Landia, becoming the Platinum Sponsor of the Pet AI community [2] - The partnership includes economic benefits from 3 million Digital Landia tokens, with PetVivo's products being promoted when the AI detects joint-related afflictions in pets [2] Product Overview - SPRYNG® with OsteoCushion® Technology is an injectable veterinary medical device that aids in managing joint pain by restoring proper joint mechanics [3] - PrecisePRP® is a first-in-class, off-the-shelf platelet-rich plasma product designed for easy use by veterinarians, providing a consistent dose of platelets without the need for blood draws [4] Technology and Market Opportunity - Digital Landia's Pet AI platform utilizes self-learning algorithms to analyze animal behavior, achieving 97% accuracy in interpreting animal communication [1][5] - The partnership targets a significant market, with 66% of U.S. households owning pets, initially engaging 123 million American pet owners and expanding internationally [6] Revenue Model and Customer Engagement - The Pet AI platform offers a freemium model and a subscription tier, allowing for tailored learning and improved accuracy through user data [7] - PetVivo will collaborate with veterinarians to deploy AI agents that provide discounts on PetVivo products, enhancing customer loyalty [8] Company Overview - PetVivo Holdings, Inc. focuses on the commercialization of innovative medical devices for companion animals, leveraging human therapies for efficient treatment [9] - The company has a robust pipeline of products and holds twenty-one patents protecting its biomaterials and methods of use [10]

MINNEAPOLIS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today it will be exhibiting at the Western Veterinary Conference to be held March 2nd to March 5th, 2025 at the Mandalay Bay Convention Center in Las Vegas, Nevada. PetVivo intends to exhibit its innovative product, SPRYNG® with OsteoCushion® Technology, an intra-articular i ...

MINNEAPOLIS, MN, US, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative therapeutics and medical devices for equines and companion animals, reported results for its fiscal third quarter ended December 31, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call today at 3:00 p.m. Eastern time to discuss the results for the period (see dial-in information below) ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 001-40715 PetVivo Holdings, Inc. (Name of small business issuer in its charter) Nevada 99-0363559 (State or other jurisdiction of ...

MINNEAPOLIS, MN, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leader in innovative veterinary medical solutions, has entered into an Exclusive License and Supply Agreement with VetStem, Inc. to commercialize VetStem’s innovative allogeneic orthobiologic products, PrecisePRP® canine and PrecisePRP® equine. PrecisePRP® is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. It is a leucoreduced, allogeneic, pooled, f ...

MINNEAPOLIS, MN, US, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and OTCPINK: PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Friday, February 14, 2025 after market close. The company will host a conference call to discuss these results at 2:00 p.m. CT (3:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materia ...

PetVivo Board Appoints Eldred as Executive Director to Lead Company Product Commercialization and Operations MINNEAPOLIS, MN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Mike Eldred as the Company's Commercialization and Operations Advisor. His appointment as an Executive Director by the Company's Board of Directors draws upon Mr. Eldred's 30 years of executive experience in ani ...

PetVivo Board Appoints Eldred as Executive Director to Lead Company Product Commercialization and Operations MINNEAPOLIS, MN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Mike Eldred as the Company’s Commercialization and Operations Advisor. His appointment as an Executive Director by the Company’s Board of Directors draws upon Mr. Eldred’s 30 years of executive experience in ani ...

Core Insights - PetVivo Holdings, Inc. will exhibit at the Veterinary Meeting & Expo Conference from January 25th to January 29th, 2025, in Orlando, Florida [1] - The company will showcase its lead product, Spryng with OsteoCushion Technology, which is designed to manage joint pain in animals [2][7] - The VMX Conference is the largest veterinary conference in the U.S., attracting top industry professionals [3] Product Information - Spryng is an intra-articular injectable veterinary medical device made of sterilized, extra-cellular matrix microparticles that integrate with the animal's subsynovial tissue [2] - The product aims to restore proper joint mechanics and manage noninfectious joint pain sources, including joint instability, degenerative joint disease, and osteoarthritis [2][7] Company Overview - PetVivo Holdings focuses on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals [6] - The company has developed a robust pipeline of products and holds a portfolio of 21 patents protecting its biomaterials and methods of use [7] - PetVivo's strategy includes developing human therapies for companion animals in a capital and time-efficient manner, allowing for quicker market entry compared to human pharmaceuticals [6]

MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) ("PetVivo"), a pioneering biomedical technology company focused on adapting human biotech, medical device and other therapeutic technologies into osteoarthritis and lameness products for commercial sale in the US companion animal and equine markets, announces new distribution partnerships with Vedco Inc. (“Vedco”), and Clipper Distributing, LLC (“Clipper”), both leaders in logistical solutions and supply of products ...